Literature DB >> 28870526

Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy.

M R Simões-Silva1, J S De Araújo1, G M Oliveira1, K C Demarque1, R B Peres1, I D'Almeida-Melo1, D G J Batista1, C F Da Silva1, C Cardoso-Santos1, P B Da Silva1, M M Batista1, M T Bahia2, M N C Soeiro3.   

Abstract

Metronidazole (Mtz) is a commercial broad-spectrum nitroimidazolic derivative with relevant antimicrobial activity and relative safety profile. Therefore, it is fair to consider Mtz a candidate for drug repurposing for other neglected conditions such as Chagas disease (CD), a parasitic pathology caused by Trypanosoma cruzi. CD is treated only with benznidazole (Bz) and nifurtimox, both introduced in clinics decades ago despite important limitations, including low efficacy on the later disease stage (chronic form) and severe side effects. New cheap and fast alternative treatments for CD are needed, thus the repurposing of Mtz was assessed in vitro and in vivo in mono- and combined therapy. In vitro assays demonstrated EC50>200µM for Mtz, while for Bz the values ranged from 2.51µM (intracellular forms) to 11.5µM (bloodstream trypomastigotes). When both drugs were combined in fixed-ratio proportions, Mtz promoted Bz potency (lower EC50 values). In vivo toxicity assays for Mtz in mice showed no adverse effects neither histopathological alterations up to 2000mg/kg. Regarding experimental T. cruzi infection, Bz 100mg/kg suppressed parasitemia while Mtz (up to 1000mg/kg) in monotherapy did not, but prolonged animal survival at 250 and 500 regimen doses. The combination of both drugs (Bz 10+Mtz 250) prevented mortality (70%) besides protected against electric cardiac alterations triggered by the parasite infection. Although not able to reduce parasite load, the combination therapy prevented animal mortality; this was possibly due to a protection of the electric cardiac physiology that is normally altered in experimental infection of T. cruzi. It also suggested that the interaction with Mtz could have improved the pharmacokinetics of Bz. Our study emphasizes the importance of drug repurposing and combined therapy for CD to contribute to alternative therapies for this neglected and silent pathology.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Combined therapy; Drug repurposing; Metronidazole; Trypanosoma cruzi

Mesh:

Substances:

Year:  2017        PMID: 28870526     DOI: 10.1016/j.bcp.2017.08.025

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Efficacy of Novel Pyrazolone Phosphodiesterase Inhibitors in Experimental Mouse Models of Trypanosoma cruzi.

Authors:  Julianna Siciliano de Araújo; Cristiane França da Silva; Denise da Gama Jaén Batista; Aline Nefertiti; Ludmila Ferreira de Almeida Fiuza; Cristina Rosa Fonseca-Berzal; Patrícia Bernardino da Silva; Marcos Meuser Batista; Maarten Sijm; Titilola D Kalejaiye; Harry P de Koning; Louis Maes; Geert Jan Sterk; Rob Leurs; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

2.  Repositioning Salirasib as a new antimalarial agent.

Authors:  Exequiel O J Porta; Ignasi Bofill Verdaguer; Consuelo Perez; Claudia Banchio; Mauro Ferreira de Azevedo; Alejandro M Katzin; Guillermo R Labadie
Journal:  Medchemcomm       Date:  2019-06-21       Impact factor: 3.597

3.  Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity.

Authors:  C F Araujo-Lima; R B Peres; P B Silva; M M Batista; C A F Aiub; I Felzenszwalb; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Refining drug administration in a murine model of acute infection with Trypanosoma cruzi.

Authors:  Julián Ernesto Nicolás Gulin; Margarita Bisio; Facundo García-Bournissen
Journal:  Lab Anim Res       Date:  2020-10-20

Review 5.  Problems associated with the use of the term "antibiotics".

Authors:  Roland Seifert; Bastian Schirmer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-09-18       Impact factor: 3.195

6.  Characterization and trypanocidal activity of a β-lapachone-containing drug carrier.

Authors:  Juliana M C Barbosa; Caroline D Nicoletti; Patrícia B da Silva; Tatiana G Melo; Débora O Futuro; Vitor F Ferreira; Kelly Salomão
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.752

7.  Combination With Tomatidine Improves the Potency of Posaconazole Against Trypanosoma cruzi.

Authors:  Marianne Rocha-Hasler; Gabriel Melo de Oliveira; Aline Nefertiti da Gama; Ludmila Ferreira de Almeida Fiuza; Anna Frieda Fesser; Monica Cal; Romina Rocchetti; Raiza Brandão Peres; Xue Li Guan; Marcel Kaiser; Maria de Nazaré Correia Soeiro; Pascal Mäser
Journal:  Front Cell Infect Microbiol       Date:  2021-03-04       Impact factor: 5.293

8.  Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.

Authors:  Juliana Magalhães Chaves Barbosa; Yasmin Pedra Rezende; Tatiana Galvão de Melo; Gabriel de Oliveira; Cynthia Machado Cascabulho; Evelyn Nunes Goulart da Silva Pereira; Anissa Daliry; Kelly Salomão Salem
Journal:  Microbiol Spectr       Date:  2022-02-09

9.  Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling.

Authors:  Alfredo Juárez-Saldivar; Michael Schroeder; Sebastian Salentin; V Joachim Haupt; Emma Saavedra; Citlali Vázquez; Francisco Reyes-Espinosa; Verónica Herrera-Mayorga; Juan Carlos Villalobos-Rocha; Carlos A García-Pérez; Nuria E Campillo; Gildardo Rivera
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

10.  Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069.

Authors:  Melisa Sayé; Lucrecia Gauna; Edward Valera-Vera; Chantal Reigada; Mariana R Miranda; Claudio A Pereira
Journal:  PLoS Negl Trop Dis       Date:  2020-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.